Gemcitabine: Current role and future options in the treatment of ovarian cancer

Erika Fruscella, Daniela Gallo, Gabriella Ferrandina, Giuseppe D'Agostino, Giovanni Scambia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients.

Original languageEnglish
Pages (from-to)81-88
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume48
Issue number1
DOIs
Publication statusPublished - Oct 2003

Fingerprint

gemcitabine
Ovarian Neoplasms
Carboplatin
Paclitaxel
Therapeutics
Combination Drug Therapy
Recurrence
Drug Therapy
Mortality

Keywords

  • Chemotherapy
  • Gemcitabine
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Gemcitabine : Current role and future options in the treatment of ovarian cancer. / Fruscella, Erika; Gallo, Daniela; Ferrandina, Gabriella; D'Agostino, Giuseppe; Scambia, Giovanni.

In: Critical Reviews in Oncology/Hematology, Vol. 48, No. 1, 10.2003, p. 81-88.

Research output: Contribution to journalArticle

Fruscella, Erika ; Gallo, Daniela ; Ferrandina, Gabriella ; D'Agostino, Giuseppe ; Scambia, Giovanni. / Gemcitabine : Current role and future options in the treatment of ovarian cancer. In: Critical Reviews in Oncology/Hematology. 2003 ; Vol. 48, No. 1. pp. 81-88.
@article{4750d713c2d74d5db5d5fef3cbb8dee4,
title = "Gemcitabine: Current role and future options in the treatment of ovarian cancer",
abstract = "Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30{\%} of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75{\%} of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients.",
keywords = "Chemotherapy, Gemcitabine, Ovarian cancer",
author = "Erika Fruscella and Daniela Gallo and Gabriella Ferrandina and Giuseppe D'Agostino and Giovanni Scambia",
year = "2003",
month = "10",
doi = "10.1016/S1040-8428(03)00119-7",
language = "English",
volume = "48",
pages = "81--88",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Gemcitabine

T2 - Current role and future options in the treatment of ovarian cancer

AU - Fruscella, Erika

AU - Gallo, Daniela

AU - Ferrandina, Gabriella

AU - D'Agostino, Giuseppe

AU - Scambia, Giovanni

PY - 2003/10

Y1 - 2003/10

N2 - Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients.

AB - Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients.

KW - Chemotherapy

KW - Gemcitabine

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0142154073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142154073&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00119-7

DO - 10.1016/S1040-8428(03)00119-7

M3 - Article

C2 - 14585485

AN - SCOPUS:0142154073

VL - 48

SP - 81

EP - 88

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -